Abstract: A grease composition containing a polymer with (a) monomers (i) at least one unsaturated &agr;,&bgr;-carboxylic acid ester containing an alkyl group with about 10 to about 20 carbon atoms; and (ii) at least one unsaturated &agr;,&bgr;-carboxylic acid ester containing an alkyl group with about 4 to about 11 carbon atoms different from monomer (i); and (iii) at least one unsaturated dicarboxylic acid anhydride or derivatives thereof; and (iv) optionally at least one unsaturated &agr;,&bgr;-carboxylic acid ester containing an alkyl group with about 1 to about 3 carbon atoms; and optionally (b) at least one non-monomeric amine with primary functionality, secondary functionality or mixtures thereof; and optionally (c) other performance additives; and (d) at least one thickening agent, and (e) an oil of lubricating viscosity. The invention further relates to the process to make the composition and its use in greases.

Abstract: The present invention relates to an apparatus and method for delivering manganese from a lubricant source into a fuel combustion system or to the exhaust therefrom. By the present invention, manganese from the lubricant will interact with phosphorus, sulfur, and/or lead from the combustion products. In this manner, the manganese scavenges or inactivates harmful materials which have migrated into the fuel or combustion products, and which can otherwise poison catalytic converters, sensors and/or automotive on-board diagnostic devices. The present invention can also lead to improved durability of exhaust after treatment systems.

Abstract: A viscosity index (VI) improver concentrate containing at least one VI improver, from 0 to about 5 mass % of lubricating oil flow improver (LOFI) and diluent oil, wherein the diluent oil has a kv100 of at least about 3.0 cSt and a CCS at −35° C. of less than 3700 cPs, and wherein at least about 98 mass % of the concentrate is composed of VI improver, LOFI and diluent oil.

Abstract: The present invention relates to a process for the selective oxidation of toluene derivatives by microbial peroxidases from microorganisms of the genus Coprinus.

Abstract: A petro-chemical free nonionic surfactant is prepared by the alkylation of an alkyl polyglucoside (APG). Under suitable alkylation reaction conditions, the surfactants are preferably prepared by the reaction of an APG with either alkyl halide or an alkyl tosylate. These surfactants are low foaming and exhibit excellent detergency.

Abstract: A cleaning formulation especially suited for cleaning a substantially vertical or inclined surfaces which is soiled by components used in the food or beverage industry. The cleaning formulation has foam characteristics as well as long cling times. Yet, it is easily rinsed from the surface.

Abstract: The present invention is directed to a disposable article that contains a plurality of substrate layers. The article is selected from the group consisting of pad sized articles, grip sized articles, sheet sized articles and combinations. These articles have a cleansing composition associated with the substrate layers. The articles provide effective cleansing benefits to the skin and hair in a convenient, inexpensive, and sanitary manner. The articles of the present invention also have superior thickness. Additionally, the article has increased rigidity while at the same time is flexible. The increase in rigidity and thickness provides for an article that does not crush or crumple during use. The article of the present invention can also provide a therapeutic or aesthetic benefit without the need for a separate benefit providing product.

Abstract: The present invention relates to granules comprising a core and a coating, wherein the core comprises an active compound and the coating comprises a wax composition with a wide molecular weight distribution.

Abstract: The laundry detergent composition of the invention contains a combination of a soap, an anionic surfactant, a nonionic surfactant, optionally a builder system, and optionally other detergent ingredients. The surfactant system comprises from 5 to 85 wt % in which the amount of soap is from 20 to 50 wt %, the amount of anionic is from 10 to 65 wt %, and the amount of nonionic is from 15 to 70 wt %, and wherein from 75 wt % to 100 wt % of the soap is present in the form of a granule which is dry-mixed with the other components, and the soap granule has a concentration of soap of at least 75 wt % based on the weight of the granule.

Abstract: Laundry treatment products comprise a graft polymer benefit agent and at least one additional laundry cleaning ingredient. The graft polymer benefit agent preferably provides soil release or fabric care benefits. The graft polymer benefit agent comprises a polysaccharide backbone and a plurality of graft chains extending from the backbone, each graft chain having a degree of polymerisation between 5 and 250. The graft polymer is substantially free of cross-linking and has a degree of substitution of grafts across a bulk sample in the range of from 0.02 to 1.0. The graft polysaccharide copolymers may be prepared using living-type free radical polymerisation techniques which provide control over the degree of substitution, the graft/co-block composition and structure.

Abstract: The invention relates to a highly alkaline or mildly alkaline detergent composition having enhanced cleaning properties. The detergent combines a source of alkalinity and a blend of nonionic surfactants that enhances cleaning waxy-fatty soils.

Abstract: The invention relates to the use of polymers of the formula (1) 1

Abstract: SARS infection has wreaks havoc in China, Hong Kong and Taiwan and its effects sending repercussion throughout the entire international society. The death rate has been high and the Chinese and western medical social were quite helpless about this. For more than hundreds of years, lung infectious diseases have always been classified under medical science as internal organs disease. However, today, this paper will point out that this opinion has been misunderstood. There is a need to associate such infection disease with air as an interface. Therefore, SARS infection is a kind surface ulcerous infection.

Abstract: The present invention provides novel compounds of the general Formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: 1

Abstract: The present invention relates to methods for use in treating or preventing infections. More particularly, the invention relates to methods for screening for modulators that inhibit cyclin-dependent kinase and the use of these putative inhibitors to control proliferation of a DNA virus that is dependent upon events associated with cell proliferation for replication. The DNA virus includes any of the herpesvirus family, and most particularly human cytomegalovirus.

Abstract: The ingestible supplement for treating muskuloskeletal disorders is made of per supplement from about 250 mg to about 2500 mg of 2-amino-2-deoxyglucose sulfate, 2-amino-2-deoxyglucose sulfate hydrochloride, n-acetyl 2-amino-2-deoxyglucose sulfate, or combinations thereof; from about 40 mg to about 750 mg of acetyl myristoleate; from about 40 mg to about 800 mg of s-adenosylmethionine; from about 200 mg to about 2000 mg of a protein; from about 100 mg to about 2500 mg of Vitamin B, Vitamin C, Vitamin E, or complexes thereof; and from about 1000 mg to about 9000 mg of a fiber. A method for improving joint mobility in a subject comprising administering to the subject an amount of the supplement involves administering to a subject an amount of the supplement on a regular basis.

Abstract: The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.

Abstract: A method for treating rosacea of the skin of a patient employs topically applying to the affected skin a composition comprising at least one peptide copper complex. In other embodiments, the present invention is directed to such a method where the composition used therefor further comprises certain disclosed active agents, including active drug and active cosmetic substances. In a related aspect, further embodiments of the present invention are directed to compositions comprising at least one peptide copper complex and certain active drug and active cosmetic substances that render the compositions particularly effective in treating rosacea.

Abstract: The invention relates to a 3′-deoxypentopyranosylnucleic acid consisting essentially of 3′-deoxypentopyranosylnucleosides of the formulae (I) or of the formulae (II) 1

Abstract: Modulating agents for inhibiting &bgr;-catenin mediated gene expression are provided. The modulating agents comprise one or more of: (1) the peptide sequence LXXLL (SEQ ID NO:1); or (2) a peptide analogue or peptidomimetic thereof. Methods for using such modulating agents for modulating &bgr;-catenin mediated gene expression and cellular differentiation in a variety of contexts (e.g., for modulating hair growth or treating cancer or Alzheimer's disease) are provided.

Abstract: Methods of using thiostrepton to treat or prevent mycobacterial infection are provided.

Abstract: Human Colon Specific Polynucleotides (DNA and RNA), Polypeptides, and Antibodies, as well as methods for using and producing such polynucleotides, polypeptides, and antibodies are disclosed. More particularly, methods are disclosed for utilizing such polynucleotides, polypeptides, and antibodies to detect, diagnose, prevent, treat, and/or ameliorate cancer (particularly gastrointestinal tract cancers such as colon and pancreatic cancer). Also disclosed are compositions and methods for targeting and destroying cancer cells (particularly gastrointestinal tract cancers such as colon and pancreatic cancer) via the Colon Specific Protein and/or via the Colon Specific Protein Receptor. Moreover, methods of screening for antagonists and binding partners of the Colon Specific Protein and therapeutic uses of such antagonists and binding partners are also disclosed.

Abstract: A therapeutic drugs for bone diseases containing as the active ingredient staniocalcin 1 which is found to have an effect of increasing bone mass. This drug for bone diseases is effective for bone diseases accompanied by anomalous osteogenesis or reduction in bone mass, such as osteoporosis, traumatic bone injuries, osteomalacia, rheumatic bone diseases, cancer-associated bone diseases, bone diseases associated with phosphorus metabolic error or calcium metabolic error, rachitis, and arthrosis deformans.

Abstract: The present invention relates to compounds according to the structure (I): 1

Abstract: The present invention provides a method of genotyping bovine for improved milk production traits by determining the GHR genotypic state of said bovine, wherein the GHR gene and polymorphisms within said gene have been found to be associated with such improved milk production traits.

Abstract: The present invention discloses the isolation and characterization of cDNA molecules encoding novel androgen receptor (AR) protein from Macaca mulatta. Also within the scope of the disclosure are recombinant vectors, recombinant host cells, methods of screening for modulators of Macaca mulatta AR (rhAR) activity, purified proteins and fusion proteins which comprise all or a portion of the rhAR protein, transgenic mice comprising a transgene encoding the rhAR protein, as well as production of antibodies against AR, or epitopes thereof.

Abstract: The invention in particular relates to the modification of human factor IX to result in factor IX proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo. The invention relates, furthermore, to T-cell epitope sequences deriving from human factor IX, which are immunogenic.

Abstract: The present invention encompasses pharmaceutical formulations comprising a biphasic mixture which comprises a glucagon like peptide (GLP-1) compound in a solid phase and an insulin in a solution phase.

Abstract: Provided herein is a chimeric protein, which chimeric protein comprises a Flt3 ligand, or a biologically active fragment thereof, and a proteinuous or peptidyl tumoricidal agent, and uses thereof, particularly in the treatment of malignancy.

Abstract: The invention relates to method for producing a glutamine-rich gluten-free peptide preparation from gluten protein, comprising the steps of enzymatically hydrolysing wheat gluten using one or more proteases to obtain a hydrolysate acidifying the hydrolysate to a pH between 4 and 5; and filtering the hydrolysate to obtain the glutamine-rich gluten-free peptide preparation as the filtrate. The protease is preferably a neutral or basic protease and the optimum pH is from 4.5 to 4.7.

Abstract: Methods for evaluating the risk of an individual to develop Alzheimer's disease using cultured neural crest-derived melanocytes are described. Also described are methods of therapy for Alzheimer's disease using peptides that bind to the neurotrophin receptor (p75NTR) and competitively inhibit the binding of &bgr;-amyloid to the p75NTR.

Abstract: This invention relates to a method of regulating apoptosis and/or proliferation in a cell, the method including the step of altering the expression and/or function in the cell of polypeptides based on Apoptosis Related Basic Protein.

Abstract: The invention describes the use of pulmonary surfactant preparations for the early treatment of acute pulmonary diseases.

Abstract: This invention provides cell-calcification inhibitory proteins as well as genes encoding the proteins. Based on the discovery of a novel isoform gene of the c-erg gene (herein referred to as “C-11 gene”) which is an erg gene derived from chickens, the nucleotide sequence of the gene has been determined, and then the expression of a protein encoded by such gene (herein referred to as “C-11 protein”) has been confirmed. Further, it has been discovered that when the c-erg or C-11 gene is introduced into osteoblasts, the calcification of the cells is inhibited.

Abstract: Disclosed are novel proteins, referred to as truncated glial cell line-derived neurotrophic factor (truncated GDNF) proteins, that promote dopamine uptake by dopaminergic cells and promote the survival of nerve cells. Also disclosed are processes for obtaining the truncated GDNF proteins by recombinant genetic engineering techniques.

Abstract: The invention includes compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator.

Abstract: The invention concerns a method for the modulation of tissue-remodeling processes, by contacting the tissue to be remodeled with a compound comprising a sequence derived from certain regions of TGF-&bgr; super family Ser/Thr/kinase receptors.

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: Reduced degeneration of an axon predetermined to be subject to degenerative neuropathy in a term patient is effected by contacting the axon in situ with an effective amount of a ubiquitin-proteasome system (UPS) inhibitor sufficient to reduce degeneration of the axon; and detecting a resultant reduction in the degeneration of the axon in situ.

Abstract: The present invention relates to compounds and methods for synthesizing compounds wherein the compounds exhibit extended circulating half-life in the blood. The increase in circulating half-life is achieved by conjugating polypeptides to binding groups that exhibit high affinity for human serum albumin.

Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.

Abstract: Intrauterine fetal growth restriction (IUGR) is a very important clinical problem for which no satisfactory treatment is available so far. The current invention of IV hypertonic glucose supplementation to the mother to improve the glucose transfer to the fetus at the intervillous space by improved facilitated diffusion can be a safe and easy way of treating this problem, as the improved fetal blood glucose can lead to fetal lipogenesis that can conserve the fetal O2 utilization, relieves the associated metabolic derangements of fetal hypoxia, hypercapnea, and acidosis, apart from replenishing the oxidized coenzymes needed for the carbohydrate metabolism. The use of transamniotic fetal feeding (TAFF), studied by animal experiments, can be difficult in humans, because of the dangers of infection, which can be overcome by the use of implantable ports with the sterile patch technique.

Abstract: Methods of increasing the tryptophan:LNAA ratio in blood of an individual are taught. Such methods are useful in managing conditions such as premenstrual syndrome, perimenopause, menopause, seasonal affective disorder, stress, or depression. The methods include orally administering specific doses of a carbohydrate blend combined with high tryptophan containing proteins.

Abstract: The present invention relates to a differentiation inducer composition for inducing differentiation of malignant cells, characterized by comprising mono-sodium 5,6-O-benzylidene-L-ascorbate (SBA) as an active ingredient, and a pharmaceutically acceptable carrier; and a use thereof. SBA is useful as a novel differentiation inducing agent showing an excellent differentiation inducing action and having extremely low toxicity.

Abstract: The present invention relates to a compound of formula (I) wherein R1 is hydrogen or together with R2 is oxo; R2 represents hydroxy, OC(O)XR7, OC(O)NHXR7 or R2 together with R1 is an oxo group; R3 is hydrogen or a hydroxyl protecting group; R4 is hydrogen or XR7; R5 is hydrogen, XR7,, C(O)XR7 or C(O)NHXR7; R6 is hydrogen or R5 and R6 taken together with the intervening atoms form a cyclic carbonate having the following structure and pharmaceutically acceptable salts and solvates thereof and solvates thereof; to processes for their preparation and their use in the therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.

Abstract: An anthelmintic composition containing as the active ingredients the first component consisting of one or more members selected from among compounds represented by the general formura (I): 1

Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: 1

Abstract: The invention concerns a method for detecting in vitro predisposition to a venous thromboembolic disease in a subject, which consists in determining whether the subject has been infected by a genus Chlamydia bacterium, in particular Chlamydia pneumoniae. The invention also concerns the use of active agents on genus Chlamydia bacteria for preventing and/or treating a venous thromboembolic disease.

Abstract: The invention provides methods of treating and preventing heat shock protein-associated diseases and conditions.

Abstract: The present invention relates to the use of ethoxylated phytosterols or phytostanols for the manufacture of an aqueous solution of a sparingly soluble substance for the prevention of cell damage in living cells.